{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:26:12Z","timestamp":1788395172262,"version":"build-2803163510"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["18158"],"award-info":[{"award-number":["18158"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>CYP2C19 phenotype is a known contributor to the interpatient variability in voriconazole response. Alternative therapy is recommended for ultrarapid\/rapid and poor metabolizers due to increased probability of subtherapeutic exposure and side effects, respectively. We aimed to evaluate whether CYP2C19 phenotype is associated with switching from voriconazole to alternative antifungal therapy, in settings where genetic results were not available at the time prescribing decisions were made.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicentre, retrospective observational study was conducted in three Australian hospitals. Patients who had previously taken voriconazole (from 1 May 2019 to 31 May 2024) were invited to undergo pharmacogenomic testing. Medical records were audited to compare switching decisions across patients with different CYP2C19 phenotypes. Differences in voriconazole exposure and voriconazole-related adverse effects were also explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 194 patients, most were normal or intermediate metabolizers (69%); 21% were rapid, 7% ultrarapid, and 3% poor metabolizers (underpowered). Switching to alternative antifungal therapy (32%; 62\/194) mainly occurred due to adverse effect incidence and was not associated with CYP2C19 phenotype (P\u200a=\u200a0.9041). C-reactive protein levels were significantly higher in patients who switched therapy (P\u200a&amp;lt;\u200a0.001). All ultrarapid metabolizers on standard voriconazole 400\u2005mg\/day had subtherapeutic concentrations and only those on higher doses (500\u20131200\u2005mg\/day) achieved therapeutic concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CYP2C19 phenotype was not predictive of switching, which is a multifactorial prescribing decision likely influenced by therapeutic drug monitoring, inflammation and clinical status. Our observations on voriconazole dosing and exposure support a complementary prescribing approach: pharmacogenomic testing to identify patients who require atypical voriconazole dosing regimens and subsequent therapeutic drug monitoring to guide dose adjustments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag168","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:11:19Z","timestamp":1777637479000},"source":"Crossref","is-referenced-by-count":1,"title":["Voriconazole therapy and\n                    <i>CYP2C19<\/i>\n                    phenotype: identifying patients who may need alternative antifungal therapy"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4317-2486","authenticated-orcid":false,"given":"Eman","family":"Wehbe","sequence":"first","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine and Health, The University of Sydney , Sydney, NSW 2006 ,","place":["Australia"]},{"name":"Department of Pharmacy, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thulashigan","family":"Sreeharan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Sutrave","sequence":"additional","affiliation":[{"name":"Westmead Institute for Medical Research, University of Sydney , Sydney, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0238-8905","authenticated-orcid":false,"given":"Jessica","family":"Bui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Royal North Shore Hospital , Sydney, NSW 2065 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2143-0646","authenticated-orcid":false,"given":"Cindy","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, St Vincent\u2019s Hospital , Sydney, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Yeun","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9457-8262","authenticated-orcid":false,"given":"Indy","family":"Sandaradura","sequence":"additional","affiliation":[{"name":"Westmead Institute for Medical Research, University of Sydney , Sydney, NSW 2145 ,","place":["Australia"]},{"name":"Centre for Infectious Diseases and Microbiology, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]},{"name":"Sydney Institute for Infectious Diseases, The University of Sydney , Sydney, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Darley","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medicine, St Vincent\u2019s Hospital , Sydney, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Macdonald","sequence":"additional","affiliation":[{"name":"Heart and Lung Transplant Unit, St Vincent's Hospital , Sydney, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Milliken","sequence":"additional","affiliation":[{"name":"Department of Haematology, St Vincent\u2019s Hospital , Sydney, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiin Nyuk","family":"Fung","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9109-7255","authenticated-orcid":false,"given":"Graham","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Chemical Pathology and Clinical Pharmacology, SydPath, St Vincent's Hospital , Sydney, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Kizny Gordon","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Microbiology, Royal North Shore Hospital , Sydney, NSW 2065 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kliman","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal North Shore Hospital , Sydney, NSW 2065 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Y","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine and Health, The University of Sydney , Sydney, NSW 2006 ,","place":["Australia"]},{"name":"Department of Pharmacy, Royal North Shore Hospital , Sydney, NSW 2065 ,","place":["Australia"]},{"name":"Kolling Institute, Faculty of Medicine and Health, The University of Sydney, The Northern Sydney Local Health District , Sydney, NSW 2065 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Marriott","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology and Infectious Diseases, St Vincent\u2019s Hospital , Sydney, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan-Willem C","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine and Health, The University of Sydney , Sydney, NSW 2006 ,","place":["Australia"]},{"name":"Department of Pharmacy, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]},{"name":"Sydney Institute for Infectious Diseases, The University of Sydney , Sydney, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-587X","authenticated-orcid":false,"given":"Sophie L","family":"Stocker","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine and Health, The University of Sydney , Sydney, NSW 2006 ,","place":["Australia"]},{"name":"Department of Pharmacy, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]},{"name":"Sydney Institute for Infectious Diseases, The University of Sydney , Sydney, NSW 2145 ,","place":["Australia"]},{"name":"Department of Clinical Pharmacology and Toxicology, St Vincent\u2019s Hospital , Sydney, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"Suppl 7","key":"2026052506263766100_dkag168-B1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/imj.15591","article-title":"Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021","volume":"51","author":"Douglas","year":"2021","journal-title":"Intern Med J"},{"key":"2026052506263766100_dkag168-B2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12879-021-05958-3","article-title":"Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response","volume":"21","author":"Neofytos","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2026052506263766100_dkag168-B3","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40121-020-00331-4","article-title":"Genetic risk surveillance for invasive aspergillosis in hematology patients: a prospective observational study","volume":"9","author":"Tanpaibule","year":"2020","journal-title":"Infect Dis Ther"},{"key":"2026052506263766100_dkag168-B4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13054-014-0722-7","article-title":"Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes","volume":"19","author":"Taccone","year":"2015","journal-title":"Crit Care"},{"issue":"Suppl 7","key":"2026052506263766100_dkag168-B5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/imj.15585","article-title":"Introduction to the updated Australasian consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology\/oncology setting, 2021","volume":"51","author":"Chang","year":"2021","journal-title":"Intern Med J"},{"issue":"Suppl 7","key":"2026052506263766100_dkag168-B6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/imj.15587","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021","volume":"51","author":"Chau","year":"2021","journal-title":"Intern Med J"},{"key":"2026052506263766100_dkag168-B7","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1093\/jac\/dkt229","article-title":"Steady-state pharmacokinetics and metabolism of voriconazole in patients","volume":"68","author":"Geist","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2026052506263766100_dkag168-B8","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026052506263766100_dkag168-B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106711","article-title":"Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial","volume":"61","author":"Veringa","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026052506263766100_dkag168-B10","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052506263766100_dkag168-B11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2026052506263766100_dkag168-B12","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2026052506263766100_dkag168-B13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"2026052506263766100_dkag168-B14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s12253-017-0264-9","article-title":"Influence of CYP2C19 genotypes on the occurrence of adverse drug reactions of voriconazole among hematological patients after Allo-HSCT","volume":"24","author":"Sienkiewicz","year":"2018","journal-title":"Pathol Oncol Res"},{"key":"2026052506263766100_dkag168-B15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijantimicag.2014.05.019","article-title":"Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity","volume":"44","author":"Dolton","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2026052506263766100_dkag168-B16","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026052506263766100_dkag168-B17","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.bcp.2007.03.012","article-title":"Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes","volume":"73","author":"Murayama","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"2026052506263766100_dkag168-B18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"2026052506263766100_dkag168-B19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/0091270008327537","article-title":"CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole","volume":"49","author":"Weiss","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"2026052506263766100_dkag168-B20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2026052506263766100_dkag168-B21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/phar.2351","article-title":"Impact of CYP2C19 genotype and drug interactions on voriconazole plasma concentrations: a Spain pharmacogenetic-pharmacokinetic prospective multicenter study","volume":"40","author":"Blanco-Dorado","year":"2020","journal-title":"Pharmacotherapy"},{"key":"2026052506263766100_dkag168-B22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/FPC.0000000000000277","article-title":"Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections","volume":"27","author":"Hamadeh","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"2026052506263766100_dkag168-B23","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052506263766100_dkag168-B24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3390\/jcm8020227","article-title":"A personalized CYP2C19 phenotype-guided dosing regimen of voriconazole using a population pharmacokinetic analysis","volume":"8","author":"Kim","year":"2019","journal-title":"J Clin Med"},{"key":"2026052506263766100_dkag168-B25","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1365-2125.2009.03534.x","article-title":"Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype","volume":"68","author":"Scholz","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"2026052506263766100_dkag168-B26","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/myc.13105","article-title":"Effect of CYP2C19 polymorphism on the plasma voriconazole concentration and voriconazole-to-voriconazole-N-oxide concentration ratio in elderly patients","volume":"63","author":"Shang","year":"2020","journal-title":"Mycoses"},{"key":"2026052506263766100_dkag168-B27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jac\/dkw349","article-title":"Voriconazole metabolism is influenced by severe inflammation: a prospective study","volume":"72","author":"Veringa","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026052506263766100_dkag168-B28","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13887","article-title":"Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole","volume":"17","author":"Klomp","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2026052506263766100_dkag168-B29","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1093\/cid\/ciaa1751","article-title":"EORTC\/MSGERC definitions of invasive fungal diseases: summary of activities of the intensive care unit working group","volume":"72","author":"Bassetti","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026052506263766100_dkag168-B30","author":"Australian Bureau of Statistics"},{"key":"2026052506263766100_dkag168-B31","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/jac\/dku031","article-title":"Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing","volume":"69","author":"Dolton","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026052506263766100_dkag168-B32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/cpt.910","article-title":"The pharmacogene variation (PharmVar) consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database","volume":"103","author":"Gaedigk","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2026052506263766100_dkag168-B33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12281-015-0219-0","article-title":"Therapeutic drug monitoring and genotypic screening in the clinical use of voriconazole","volume":"9","author":"Moriyama","year":"2015","journal-title":"Curr Fungal Infect Rep"},{"key":"2026052506263766100_dkag168-B34","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.3390\/jcm10102089","article-title":"Combined impact of inflammation and pharmacogenomic variants on voriconazole trough concentrations: a meta-analysis of individual data","volume":"10","author":"Bolcato","year":"2021","journal-title":"J Clin Med"},{"key":"2026052506263766100_dkag168-B35","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/bcp.14995","article-title":"Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: availability, performance and barriers to implementation","volume":"88","author":"Sandaradura","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026052506263766100_dkag168-B36","author":"Kwang"},{"key":"2026052506263766100_dkag168-B37","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/cpt.1642","article-title":"Evaluation of CYP2C19 genotype-guided voriconazole prophylaxis after allogeneic hematopoietic cell transplant","volume":"107","author":"Patel","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2026052506263766100_dkag168-B38","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3390\/pharmaceutics16050677","article-title":"Therapeutic drug monitoring and biomarkers; towards better dosing of antimicrobial therapy","volume":"16","author":"Wehbe","year":"2024","journal-title":"Pharmaceutics"},{"key":"2026052506263766100_dkag168-B39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037443","article-title":"Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol","volume":"10","author":"Monserrat Villatoro","year":"2020","journal-title":"BMJ Open"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/6\/dkag168\/68333974\/dkag168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/6\/dkag168\/68333974\/dkag168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T10:26:44Z","timestamp":1779704804000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag168\/8687259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag168","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,5]]},"article-number":"dkag168"}}